Feldman M, et al., eds. Epidemiology, pathogenesis, and diagnosis of inflammatory bowel diseases. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 11th ed. Elsevier; 2021. https://www.clinicalkey.com. Accessed July 22, 2020.
Goldman L, et al., eds. Inflammatory bowel disease. In: Goldman-Cecil Medicine. 26th ed. Elsevier; 2020. https://www.clinicalkey.com. Accessed July 22, 2020.
The facts about inflammatory bowel diseases. Crohn's and Colitis Foundation. https://site.crohnscolitisfoundation.org/resources/facts-about-inflammatory.html. Accessed July 22, 2020.
Crohn's disease. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/digestive-diseases/crohns-disease. Accessed July 22, 2020.
Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. JAMA. 2016; doi:10.1001/jama.2016.5989.
Kliegman RM. Inflammatory bowel diseases. In: Nelson Textbook of Pediatrics. 21st ed. Elsevier; 2020. https://www.clinicalkey.com. Accessed July 22, 2020.
Lichtenstein GR, et al. ACG clinical guideline: Management of Crohn's disease in adults. American Journal of Gastroenterology. 2018; doi:10.1038/ajg.2018.27.
Abraham B, et al. Antibiotics and probiotics in inflammatory bowel disease: When to use them? Frontline Gastroenterology. 2020; doi:10.1136/flgastro-2018-101057.
What should I eat? Crohn's and Colitis Foundation. https://www.crohnscolitisfoundation.org/diet-and-nutrition/what-should-i-eat. Accessed July 27, 2020.
Mind-body therapies. Crohn's and Colitis Foundation. https://www.crohnscolitisfoundation.org/complementary-medicine/mind-body-therapies. Accessed July 27, 2020.
Ami TR. Allscripts EPSi. Mayo Clinic. April 15, 2022.
Kane SV (expert opinion). Mayo Clinic. Sept. 11, 2020.
Khanna S (expert opinion). Mayo Clinic. July 27, 2022.
Xeljanz, Xeljanz XR (tofacitinib): Drug safety communication — Initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine. U.S. Food and Drug Administration. https://www.fda.gov/safety/medical-product-safety-information/xeljanz-xeljanz-xr-tofacitinib-drug-safety-communication-initial-safety-trial-results-find-increased?utm_medium=email&utm_source=govdelivery. Accessed Aug. 1, 2022.
Cohen RD, et al. Management of moderate to severe ulcerative colitis in adults. https://www.uptodate.com/contents/search. Accessed Aug. 1, 2022.